COMP <GO>
LFVN vs MRK // PIOTROSKI F-SCORE QUALITY
Lifevantage Corporation (Delaware) (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: LFVN 8
— MRK 5
▲ PIOTROSKI F-SCORE QUALITY LEADER: LFVN
LAST: $5.88 (+0.17%) • MKT CAP: $73.9M
piotroski-score
8/9
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
piotroski-score
7/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LFVN VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LFVN | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 80.40% | 74.80% | +5.60 | LFVN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 29.20% | 20.70% | +8.50 | LFVN | /roic <GO> |
| EV/EBITDA & P/E Valuation | 5.5x | 15.3x | -9.80 | LFVN | /valuation <GO> |
| Free Cash Flow Yield | 14.22% | 3.42% | +10.80 | LFVN | /fcf-yield <GO> |
| Operating Margin | 5.30% | 34.30% | -29.00 | MRK | /operating-margins <GO> |
| Net Profit Margin | 4.30% | 28.10% | -23.80 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 14.20% | 1.30% | +12.90 | LFVN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.80% | 2.26% | +0.54 | LFVN | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.98 | 5.19 | -1.21 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 8/9 | 7/9 | +1.00 | LFVN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.6 | 51.7 | -2.08 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 6.3x | 18.4x | -12.10 | LFVN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $73.9M | $361.02B | -$360.95B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LFVN REV | MRK REV | LFVN GROSS % | MRK GROSS % | LFVN FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $228.5M | $65.01B | 80.4% | 74.8% | $10.5M | $12.36B |
| FY 2024 | $200.2M | $64.17B | 79.3% | 76.3% | $10.0M | $18.10B |
| FY 2023 | $213.4M | $60.12B | — | — | $6.8M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LFVN // BETA —
MRK // BETA 0.92